Adaptive Biotechnologies Corp
For the period ended Nov 4, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 4, 2026 · Filed Nov 4, 2026
Use the contents to explore the available documents and sections.
ADPT$27.98+4.3%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Segment Information (Including Segment Adjusted EBITDA)
Segment Information (Including Segment Adjusted EBITDA)
The following sets forth segment information for the periods presented (in thousands, unaudited):
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| MRD: | ||||
| Revenue | $72,565 | $56,788 | $205,826 | $150,447 |
| Adjusted EBITDA | 15,119 | 6,965 | 36,373 | 4,766 |
| Reconciliation of Net Income (Loss) to Adjusted EBITDA: | ||||
| Net income (loss) | $6,483 | $(2,042) | $10,227 | $(21,460) |
| Depreciation and amortization expense | 2,475 | 2,470 | 7,265 | 7,588 |
| Impairment of long-lived assets | — | — | — | — |
| Restructuring expense | — | — | 325 | — |
| Share-based compensation expense | 6,161 | 6,537 | 18,556 | 18,638 |
| Adjusted EBITDA | $15,119 | $6,965 | $36,373 | $4,766 |
| Immune Medicine(1): | ||||
| Revenue | $11,337 | $37,185 | $20,503 | $54,848 |
| Adjusted EBITDA | 3,238 | 24,111 | (13,391) | 13,284 |
| Reconciliation of Net (Loss) Income to Adjusted EBITDA: | ||||
| Net (loss) income | $(434) | $18,182 | $(26,418) | $(4,507) |
| Depreciation and amortization expense | 665 | 1,470 | 2,496 | 4,678 |
| Impairment of long-lived assets | — | — | 347 | — |
| Restructuring expense | 712 | — | 1,107 | — |
| Share-based compensation expense | 2,295 | 4,459 | 9,077 | 13,113 |
| Adjusted EBITDA | $3,238 | $24,111 | $(13,391) | $13,284 |
(1)Expenses related to Digital Biotechnologies, Inc. are no longer included in the Immune Medicine segment.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.